{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,6]],"date-time":"2025-12-06T17:17:31Z","timestamp":1765041451614,"version":"3.37.3"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,2,6]],"date-time":"2024-02-06T00:00:00Z","timestamp":1707177600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,2,6]],"date-time":"2024-02-06T00:00:00Z","timestamp":1707177600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Honoraria\/ research support: Janssen, GSK, Pfizer, Sanofi."},{"name":"Honoraria\/ research support: Karyopharm X4 Pharmaceuticals, GSK, Takeda, Janssen, Amgen, Celgene\/Genesis, Sanofi;"},{"name":"MK is a Janssen employee"},{"name":"Honoraria\/ research support: Amgen, BMS, ASTRAZeneca, EUSA Pharma, GSK, Janssen, Menarini\/Stemline, Pfizer, Sanofi, Takeda;"},{"name":"Honoraria\/ research support: AbbVie, Amgen, Bristol Myers Squibb, BeiGene Inc, GSK, Janssen, Menarini, Regeneron, Sanofi, Takeda"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"DOI":"10.1038\/s41408-024-00988-x","type":"journal-article","created":{"date-parts":[[2024,2,6]],"date-time":"2024-02-06T06:02:20Z","timestamp":1707199340000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Efficacy and immune modulation associated with the addition of IMiDs to Daratumumab backbone in multiple myeloma patients refractory to both drug classes: resetting synergistic activity"],"prefix":"10.1038","volume":"14","author":[{"given":"Ioannis V.","family":"Kostopoulos","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0618-8900","authenticated-orcid":false,"given":"Despina","family":"Fotiou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6244-1229","authenticated-orcid":false,"given":"Maria","family":"Gavriatopoulou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pantelis","family":"Rousakis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6328-9783","authenticated-orcid":false,"given":"Ioannis","family":"Ntanasis-Stathopoulos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chrysanthi","family":"Panteli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Panagiotis","family":"Malandrakis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Magdalini","family":"Migkou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nikolaos","family":"Angelis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nikolaos","family":"Kanellias","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Evangelos","family":"Eleutherakis-Papaiakovou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Foteini","family":"Theodorakakou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Krevvata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5133-1422","authenticated-orcid":false,"given":"Evangelos","family":"Terpos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8990-3254","authenticated-orcid":false,"given":"Meletios-Athanasios","family":"Dimopoulos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6954-0740","authenticated-orcid":false,"given":"Ourania","family":"Tsitsilonis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8191-5832","authenticated-orcid":false,"given":"Efstathios","family":"Kastritis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,2,6]]},"reference":[{"key":"988_CR1","doi-asserted-by":"publisher","first-page":"e105","DOI":"10.1016\/S1470-2045(20)30756-7","volume":"22","author":"P Moreau","year":"2021","unstructured":"Moreau P, Kumar SK, San Miguel J, Davies F, Zamagni E, Bahlis N, et al. Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group. Lancet Oncol. 2021;22:e105\u201318.","journal-title":"Lancet Oncol"},{"key":"988_CR2","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1016\/j.clml.2022.01.011","volume":"22","author":"MA Dimopoulos","year":"2022","unstructured":"Dimopoulos MA, Richardson P, Lonial S. Treatment options for patients with heavily pretreated relapsed and refractory multiple myeloma. Clin Lymphoma Myeloma Leuk. 2022;22:460\u201373.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"988_CR3","doi-asserted-by":"publisher","first-page":"2266","DOI":"10.1038\/s41375-019-0435-7","volume":"33","author":"UH Gandhi","year":"2019","unstructured":"Gandhi UH, Cornell RF, Lakshman A, Gahvari ZJ, McGehee E, Jagovsky MH, et al. Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy. Leukemia. 2019;33:2266\u201375.","journal-title":"Leukemia"},{"key":"988_CR4","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1038\/s41375-022-01531-2","volume":"36","author":"MV Mateos","year":"2022","unstructured":"Mateos MV, Weisel K, De Stefano V, Goldschmidt H, Delforge M, Mohty M, et al. LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and\/or refractory multiple myeloma. Leukemia. 2022;36:1371\u20136.","journal-title":"Leukemia"},{"key":"988_CR5","doi-asserted-by":"publisher","first-page":"2991","DOI":"10.1002\/cncr.32178","volume":"125","author":"AK Nooka","year":"2019","unstructured":"Nooka AK, Joseph NS, Kaufman JL, Heffner LT, Gupta VA, Gleason C, et al. Clinical efficacy of daratumumab, pomalidomide, and dexamethasone in patients with relapsed or refractory myeloma: utility of re-treatment with daratumumab among refractory patients. Cancer. 2019;125:2991\u20133000.","journal-title":"Cancer"},{"key":"988_CR6","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1182\/blood-2017-10-809293","volume":"131","author":"M Gavriatopoulou","year":"2018","unstructured":"Gavriatopoulou M, Kastritis E, Ntanasis-Stathopoulos I, Fotiou D, Rousou M, Migkou M, et al. The addition of IMiDs for patients with daratumumab-refractory multiple myeloma can overcome refractoriness to both agents. Blood. 2018;131:464\u20137.","journal-title":"Blood"},{"key":"988_CR7","doi-asserted-by":"publisher","first-page":"4290","DOI":"10.1158\/1078-0432.CCR-16-3192","volume":"23","author":"X Feng","year":"2017","unstructured":"Feng X, Zhang L, Acharya C, An G, Wen K, Qiu L, et al. Targeting CD38 suppresses induction and function of T regulatory cells to mitigate immunosuppression in multiple myeloma. Clin Cancer Res. 2017;23:4290\u20134300.","journal-title":"Clin Cancer Res"},{"key":"988_CR8","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1182\/blood-2015-12-687749","volume":"128","author":"J Krejcik","year":"2016","unstructured":"Krejcik J, Casneuf T, Nijhof IS, Verbist B, Bald J, Plesner T, et al. Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma. Blood. 2016;128:384\u201394.","journal-title":"Blood"},{"key":"988_CR9","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1080\/13506129.2021.1971192","volume":"28","author":"E Kastritis","year":"2021","unstructured":"Kastritis E, Rousakis P, Kostopoulos IV, Gavriatopoulou M, Theodorakakou F, Fotiou D, et al. Consolidation with a short course of daratumumab in patients with AL amyloidosis or light chain deposition disease. Amyloid. 2021;28:259\u201366.","journal-title":"Amyloid"},{"key":"988_CR10","doi-asserted-by":"publisher","first-page":"860","DOI":"10.3389\/fonc.2020.00860","volume":"10","author":"IV Kostopoulos","year":"2020","unstructured":"Kostopoulos IV, Ntanasis-Stathopoulos I, Gavriatopoulou M, Tsitsilonis OE, Terpos E. Minimal residual disease in multiple myeloma: current landscape and future applications with immunotherapeutic approaches. Front Oncol. 2020;10:860.","journal-title":"Front Oncol"},{"key":"988_CR11","doi-asserted-by":"publisher","first-page":"e881","DOI":"10.1097\/HS9.0000000000000881","volume":"7","author":"CPM Verkleij","year":"2023","unstructured":"Verkleij CPM, Frerichs KA, Broekmans MEC, Duetz C, O\u2019Neill CA, Bruins WSC, et al. NK cell phenotype is associated with response and resistance to daratumumab in relapsed\/refractory multiple myeloma. HemaSphere. 2023;7:e881.","journal-title":"HemaSphere"},{"key":"988_CR12","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1038\/s41375-020-0810-4","volume":"35","author":"D Viola","year":"2021","unstructured":"Viola D, Dona A, Caserta E, Troadec E, Besi F, McDonald T, et al. Daratumumab induces mechanisms of immune activation through CD38+ NK cell targeting. Leukemia. 2021;35:189\u2013200.","journal-title":"Leukemia"},{"key":"988_CR13","doi-asserted-by":"publisher","first-page":"112685","DOI":"10.18632\/oncotarget.22340","volume":"8","author":"X Chen","year":"2017","unstructured":"Chen X, Chen J, Zhang W, Sun R, Liu T, Zheng Y, et al. Prognostic value of diametrically polarized tumor-associated macrophages in multiple myeloma. Oncotarget. 2017;8:112685\u201396.","journal-title":"Oncotarget"},{"key":"988_CR14","doi-asserted-by":"publisher","first-page":"e003975","DOI":"10.1136\/jitc-2021-003975","volume":"10","author":"J Sun","year":"2022","unstructured":"Sun J, Park C, Guenthner N, Gurley S, Zhang L, Lubben B, et al. Tumor-associated macrophages in multiple myeloma: advances in biology and therapy. J Immunother Cancer. 2022;10:e003975.","journal-title":"J Immunother Cancer"},{"key":"988_CR15","doi-asserted-by":"publisher","first-page":"3245","DOI":"10.3390\/cancers12113245","volume":"12","author":"K Papadimitriou","year":"2020","unstructured":"Papadimitriou K, Tsakirakis N, Malandrakis P, Vitsos P, Metousis A, Orologas-Stavrou N, et al. Deep phenotyping reveals distinct immune signatures correlating with prognostication, treatment responses, and MRD status in multiple myeloma. Cancers. 2020;12:3245.","journal-title":"Cancers"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-024-00988-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-024-00988-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-024-00988-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T10:03:29Z","timestamp":1707473009000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-024-00988-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,6]]},"references-count":15,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["988"],"URL":"https:\/\/doi.org\/10.1038\/s41408-024-00988-x","relation":{},"ISSN":["2044-5385"],"issn-type":[{"type":"electronic","value":"2044-5385"}],"subject":[],"published":{"date-parts":[[2024,2,6]]},"assertion":[{"value":"28 August 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 December 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 January 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 February 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"MG Honoraria\/ research support: Karyopharm X4 Pharmaceuticals, GSK, Takeda, Janssen, Amgen, Celgene\/Genesis, Sanofi; MK is a Janssen employee; ET Honoraria\/ research support: Amgen, BMS, ASTRAZeneca, EUSA Pharma, GSK, Janssen, Menarini\/Stemline, Pfizer, Sanofi, Takeda; MAD Honoraria\/ research support: AbbVie, Amgen, Bristol Myers Squibb, BeiGene Inc, GSK, Janssen, Menarini, Regeneron, Sanofi, Takeda; EK Honoraria\/ research support: Janssen, GSK, Pfizer, Sanofi.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"26"}}